

Division of Signal Transduction Therapy

Standard Operating Procedure

Preparation of active MARK1 [2 - 795]

<u>Enzyme description:-</u>	MARK1 [2 – 795]
<u>Clone number:-</u>	DU 1272
<u>Source:-</u>	Recombinant
<u>Expression system:-</u>	Baculovirus expression vector system
<u>Tag:-</u>	N-terminal His(6) tag
<u>Purification method:-</u>	Ni ²⁺ -NTA agarose

Calculated molecular mass:-

Monoisotopic 92, 529.72 daltons
Average Mass 92, 587.41 daltons
[cysteines reduced, methionines have not been oxidised]

Theoretical pI:- 9.24

Purity:- 80 %

Activation protocol:- Constitutively active

Enzyme storage buffer:-

50 mM Tris-HCl pH 7.5, 270 mM sucrose, 150 mM NaCl, 0.1 mM EGTA,
0.1 % 2-mercaptoethanol, 0.02 % Brij-35, 0.2 mM PMSF, 1 mM Benzamidine.

Storage temperature:- -70 °C

Assay Buffer:-

50 mM Tris-HCl pH 7.5, 0.1mM EGTA, 0.1 % 2-mercaptoethanol, 10 mM MgAc

Substrate:-

CHKtide peptide [KKKVSRSGLYRSPSPENLNRPR]
Final concentration: 300 μ M

Division of Signal Transduction Therapy

Clone Data Sheet

MARK1 [2 - 795]

Protein MARK1 [2 – 795]

Clone Number DU 1272

Species Human

Accession number AF154845

Tags N-terminal His(6)

Baculovirus expressed protein MSYYHHHHHHHDYDIPTTENLYFQ~~G~~AMDPEFSARTPLPTVNERD~~T~~ENHTS
VDGYTEPHIQPTKSSSRQNI~~P~~RCRNSITSATDEQPHIGNYRLQKTIGKG
NFAKVKLARHVL~~T~~GREVAVKI~~I~~DKTQLNPTSLQKLFREVRIMKILNHPN
IVKLF~~E~~VIET~~E~~KTL~~Y~~LVMEYASGGEVFDYLVAHGRMKEKEARAKFRQIV
SAVQYCHQKYIVHRDLKAENLLLDGDMNIKIADFGFSNEFTVGNKLDTF
CGSPPYAAPELFQ~~G~~GKKYDGPEVDVWSLGVILYTLVSGSLPFDGQNLKEL
RERVLRGKYRIPFYMSTDCENLLKLLVLNPIKRGSL~~E~~QIMKDRWMNVG
HEEEELKPYTEPD~~P~~DFNDTKRIDIMVTMGFARDEINDALINQKYDEVMA
TYILLGRKPPEFEGGESLSSGNLCQ~~R~~SRPSSDLNNSTLQSPAH~~L~~KVQ~~R~~S
ISANQKQRRFSDHAGPSIPPAVSYTKRPQANSVESEQKEEWDKDVARKL
GSTTVGSKSEMTASPLVGPERKKSS~~T~~IPSNVYSGGSMARRNTYVCERT
TD~~R~~YVALQNGKDSSLTEMSVSSISSAGSSVASAVPSARPRHQKSMSTSG
HPIKVTLPTIKDGSEAYRPGTTQ~~R~~VPAASPSAHSISTATPD~~R~~TRFPRGS
SSRSTFHGEQLRERRSVAYNGPPASPSHETGAF~~A~~HARRGTSTGIISKIT
SKFVRRDPSEGEASGR~~T~~DTSRSTSGEPKERDKEEGKDSKPRSLRFTWSM
KTTSSMDPN~~D~~MMREIRKVL~~D~~ANNCDYEQKERFLLFCVHG~~D~~ARQDSL~~V~~QW
EMEVCKLPRLSLNGVRFKRISGTSIAFKNIASKIANELKL

Native sequence Amino acids S2 – L795 (end) of human MARK1.
Residue S31 of fusion protein is equivalent to S2 of the native enzyme.
The His(6) tag is located at residues 5 – 10.

The following amino acid substitutions are present:
V – ~~E~~, where V16 of the native enzyme is E45 of the fusion protein
T – ~~S~~, where T20 of the native enzyme is S49 of the fusion protein

Protease cleavage rTEV (ENLYFQG) residues 18 - 24

Cloning sites *Eco*R1 site of pFastBAC HTa

Division of Signal Transduction Therapy

Nucleotide sequence of insert

gaattcTCGGCCCGGACGCCATTGCCGACGGTGAACGAGCGGGACACGG
AAAATCATACATCTGTGGATGGATATACTGAACCACACATCCAGCCTAC
CAAGTCGAGTAGCAGACAGAACATCCCCGGTGTAGAACTCCATTACG
TCAGCAACAGATGAACAGCCTCACATTGGAAATTACCGTTTACAAAAA
CAATAGGGAAGGGAAATTTTGCCAAAGTCAAATTGGCAAGACACGTTCT
AACTGGTAGAGAGGTTGCTGTGAAAATAATAGACAAAACCTCAGCTAAAT
CCTACCAGTCTACAAAAGTTATTTTCGAGAAGTACGAATAATGAAGATAC
TGAATCATCCTAATATAGTAAAATTGTTTGAAGTTATTGAAACAGAGAA
GACTCTCTATTTAGTCATGGAATACGCGAGTGGGGGTGAAGTATTTGAT
TACTTAGTTGCCCATGGAAGAATGAAAGAGAAAAGAGGCCCGTGCAAAAT
TTAGGCAGATTGTATCTGCTGTACAGTATTGTCATCAAAGTACATTGT
TCACCGTGATCTTAAGGCTGAAAACCTTCTCCTTGATGGTGATATGAAT
ATTAAAATTGCTGACTTTGGTTTTAGTAATGAATTTACAGTTGGGAACA
AATTGGACACATTTTGTGGAAGCCCACCTATGCTGCTCCCGAGCTTTT
CCAAGGAAAGAAGTATGATGGGCCTGAAGTGGATGTGTGGAGTCTGGGC
GTCATTCTCTATACATTAGTCAGTGGCTCCTTGCCTTTCGATGGCCAGA
ATTTAAAGGAAGTGCAGAGCGAGTTTTACGAGGGAAGTACCGTATTCC
CTTCTATATGTCCACAGACTGTGAAAATCTTCTGAAGAAATTATTAGTC
CTGAATCCAATAAAGAGAGGCAGCTTGGAACAAATAATGAAAGATCGAT
GGATGAATGTTGGTCATGAAGAGGAAGAACTAAAGCCATATACTGAGCC
TGATCCGGATTTCAATGACACAAAAAGAATAGACATTATGGTCACCATG
GGCTTTGCACGAGATGAAATAAATGATGCCTTAATAAATCAGAAGTATG
ATGAAGTTATGGCTACTTATATTCTTCTAGGTAGAAAACCACCTGAATT
TGAAGGTGGTGAATCGTTATCCAGTGGAACTTGTGTGAGAGGTCCCGG
CCCAGTAGTGACTTAAACAACAGCACTCTTCAGTCCCCTGCTCACCTGA
AGGTCCAGAGAAGTATCTCAGCAAATCAGAAGCAGCGGCGTTTCAGTGA
TCATGCTGGTCCATCCATTCCTCCTGCTGTATCATATACCAAAGACCT
CAGGCTAACAGTGTGGAAGTGAACAGAAAGAGGAGTGGGACAAAGATG
TGGCTCGAAAACCTGGCAGCACAAACAGTTGGATCAAAAAGCGAGATGAC
TGCAAGCCCCTCTTGTAGGGCCAGAGAGGAAAAAATCTTCAACTATTCCA
AGTAACAATGTGTATTCTGGAGGTAGCATGGCAAGAAGGAATACATATG
TCTGTGAAAGGACCACAGATCGATACGTAGCATTCGAGAATGGAAAAGA
CAGCAGCCTTACGGAGATGTCTGTGAGTAGCATATCTTCTGCAGGCTCT
TCTGTGGCCTCTGCTGTCCCCTCAGCACGACCCCGCCACCAGAAGTCCA
TGTCCACTTCTGGTCATCCTATTAAAGTCACACTGCCAACCATTAAAGA
CGGCTCTGAAGCTTACCGGCCTGGTACAACCCAGAGAGTGCCTGCTGCT
TCCCCATCTGCTCACAGTATTAGTACTGCGACTCCAGACCGGACCCGTT
TTCCCCGAGGGAGCTCAAGCCGAAGCACTTTCCATGGTGAACAGCTCCG
GGAGCGACGCAGCGTTGCTTATAATGGGCCACCTGCTTCACCATCCCAT
GAAACGGGTGCATTTGCACATGCCAGAAGGGGAACGTCAACTGGTATAA
TAAGCAAAATCACATCCAAATTTGTTTCGAGGGATCCAAGTGAAGGCGA
AGCCAGTGGCAGAACCGACACCTCAAGAAGTACATCAGGGGAACCAAAA
GAAAGAGACAAGGAAGAGGGTAAAGATTCTAAGCCGCGTTCTTTGCGGT
TCACATGGAGTATGAAGACCACTAGTTCAATGGACCCTAATGACATGAT
GAGAGAAATCCGAAAAGTGTTAGATGCAAATAACTGTGATTATGAGCAA
AAAGAGAGATTTTTGCTTTTCTGTGTCCATGGAGACGCTAGACAGGATA
GCCTCGTGAGTGGGAGATGGAAGTCTGCAAGTTGCCACGACTGTCACT

Division of Signal Transduction Therapy

TAAATGGGGTTCGCTTCAAGCGAATATCTGGGACATCTATTGCCTTTAAG
AACATTGCATCAAAAATAGCAAATGAGCTTAAGCTGtaagaattc